TRA2B

Across TCGA pan-cancer cohorts, TRA2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRA2B data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRA2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRA2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where TRA2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.974	0.725	<.001	36	view →
HNSC	DFS	Tertile	All	0.286	0.966	.006	28	view →
LSCC	DFS	Median	All	0.847	0.612	.008	21	view →
COAD	DFS	Median	All	1.000	0.888	.023	18	view →
PDAC	DFS	Tertile	III,IV	0.237	0.600	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRA2B–LUAD (OS)

Open the LUAD breakdown →